



[www.genfit.com](http://www.genfit.com)

## **GENFIT: CONVERSION INTO SHARES OF 15 BONDS OCA2012-2**

**Lille (France), Boston (Massachusetts, United States), April 2<sup>nd</sup>, 2013** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the conversion into shares of 15 bonds OCA2012-2 in keeping with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.

In keeping with the 1<sup>st</sup> and 2<sup>nd</sup> resolutions of the Extraordinary Shareholders' Meeting held on December 18th, 2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), the Bondholder requested this conversion of 15 bonds OCA2012-2 on March 28<sup>th</sup>, 2013 for a value of €150,000.

The conversion into 27,656 new shares was performed at a conversion rate of €5.42, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (March 21<sup>th</sup>, 2013- March 27<sup>th</sup>, 2013) prior to the conversion request.

As a result of this conversion reserved to the Bondholder:

- The social capital of GENFIT has increased from €4,306,168 to €4,313,082;
- The number of shares representing the social capital of GENFIT has increased by 27,656, from 17,224,672 to 17,252,328 shares;
- The amount of the 6th installment of the bond loan agreement that remains to be converted is €850,000.

### **About GENFIT:**

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### **Contacts:**

#### **GENFIT**

Jean-François Mouney – CEO & Chairman of the Management Board  
Ph. +333 2016 4000

**MILESTONES – Press Relations**

Bruno Arabian Ph. +33 1 7544 8740 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)